insights_auto
Защо EVT бележи спад 8,76%?
По-подробно разглежданеchevron_right
EVT:FRA
Evotec SE
2,83 €
arrow_downward
-8,76%(-0,27) 1 д.
7.10, 22:00:00 ч. Гринуич+2 · EUR
search
Всички символи
| Символ | Цена | Промяна | % промяна |
|---|
insights_autoГенерира се водещата статистика за EVT…
Отваряне
2,96 €
Висока
2,96 €
Ниска
2,83 €
Пазарна кап.
479,99 млн.
Ср. обем
4,58 хил.
Обем
1,90 хил.
Най-висока цена за 52 седм.
7,49 €
Най-ниска цена за 52 седм.
2,73 €
EPS
-1,11 €
Акции в обращение
148,72 млн.
Брой служители
4 хил.
Отваряне
2,96 €
Висока
2,96 €
Ниска
2,83 €
Пазарна кап.
479,99 млн.
Ср. обем
4,58 хил.
Обем
1,90 хил.
Най-висока цена за 52 седм.
7,49 €
Най-ниска цена за 52 седм.
2,73 €
EPS
-1,11 €
Акции в обращение
148,72 млн.
Брой служители
4 хил.
Новинарски материали
От източници в мрежата и новинарски партньори
AD HOC NEWS
·
преди 9 часа
Evotec loses research chief. Evotec stock falls 2.03 percent
AD HOC NEWS
·
преди 1 ден
Evotec loses research chief and Evotec stock gains 2.36 percent
AD HOC NEWS
·
преди 3 месеца
Evotec stock after-hours at EUR 2.95: minus 0.67 percent versus prior close
Профил
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Всичко за Evotec SE
Главен изпълнителен директор-
Служители4,46 хил.
Дата на основаване1993
Централен офис-
Бранш-
Уебсайтevotec.com